Stock LEGN LEGEND BIOTECH CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
46.3 USD +0.85% Intraday chart for Legend Biotech Corporation +4.54% -23.05%
Jul. 04 Genscript Biotech's Phase 3 Multiple Myeloma Drug Trial Yields Positive Results MT
Jul. 02 Legend Biotech Says Myeloma Drug Shows Positive Overall Survival Results MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
GL
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
AQ
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
BU
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
BU
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
BU
Legend Biotech : LEGN Q1 2024 Earnings Presentation
PU
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
BU
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BU
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2024 - Form 6-K
PU
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
BU
Innovative personalised immunotherapy approved for multiple myeloma
AQ
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
BU
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance Report
AQ
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
BU
CARVYKTI (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
AQ
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
BU
Legend Biotech : Sponsor and FDA Briefing Books Released Prior to U.S. FDA Oncologic Drugs Advisory Committee Meeting for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) - Form 6-K
PU
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
BU
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
AQ
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. News Legend Biotech Corporation
  5. Press Releases